SIQING FU

TitleAssociate Professor
InstitutionMD Anderson
DepartmentInvestigational Cancer Therapeutics
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang H, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F. Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. Clin Cancer Res. 2020 Oct 28. PMID: 33115815.
      Citations:    Fields:    
    2. Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, Fu S, Hollmann TJ, Iasonos A, Konner JA, Konstantinopoulos PA, Modesitt SC, Sharon E, Aghajanian C, Zamarin D. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer. 2020 Oct; 8(2). PMID: 33004542.
      Citations:    Fields:    
    3. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 Oct; 8(2). PMID: 33097611.
      Citations:    Fields:    
    4. Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, Goff L, Laing N, Mi G, Oliveira JM, Wasserstrom H, Lin CC. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020 Sep; 137:272-284. PMID: 32827847.
      Citations:    Fields:    
    5. Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020 Aug 16; 12(8). PMID: 32824391.
      Citations:    
    6. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968. PMID: 32553118.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Saleh M, Cassier PA, Eberst L, Naik G, Morris VK, Pant S, Terret C, Gao L, Long A, Mao H, McNeely S, Wagner EK, Carlesi RM, Fu S. Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. Oncologist. 2020 Jun 14. PMID: 32537847.
      Citations:    Fields:    
    8. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7. PMID: 32337094.
      Citations:    
    9. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1). PMID: 32188704.
      Citations: 1     Fields:    
    10. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080. PMID: 32080210.
      Citations:    Fields:    
    11. Tsimberidou AM, Hong DS, Wheler JJ, Falchook GS, Janku F, Naing A, Fu S, Piha-Paul S, Cartwright C, Broaddus RR, Nogueras Gonzalez GM, Hwu P, Kurzrock R. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145. PMID: 31888672.
      Citations:    Fields:    Translation:Humans
    12. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 Apr 15; 26(8):1924-1931. PMID: 31852833.
      Citations: 2     Fields:    
    13. Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246. PMID: 31822497.
      Citations: 2     Fields:    
    14. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253. PMID: 31533818.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    15. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158. PMID: 31445783.
      Citations:    Fields:    
    16. Zhou X, Lockhart AC, Fu S, Nemunaitis J, Sarantopoulos J, Muehler A, Rangachari L, Bargfrede M, Venkatakrishnan K. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. J Clin Pharmacol. 2019 09; 59(9):1204-1215. PMID: 30985952.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    17. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348. PMID: 30869638.
      Citations: 1     Fields:    Translation:Humans
    18. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773. PMID: 30347019.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    19. Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2019 03; 9(3):384-395. PMID: 30487236.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    20. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270. PMID: 30279957.
      Citations: 1     Fields:    
    21. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243. PMID: 30237864.
      Citations: 2     Fields:    
    22. Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610. PMID: 30181387.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    23. Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885. PMID: 30182147.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    24. Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018 09; 82(3):419. PMID: 30014222.
      Citations:    Fields:    
    25. Fu S, Wang Y, Keyomarsi K, Meric-Bernstein F. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs. 2018 09; 27(9):741-751. PMID: 30102076.
      Citations: 7     Fields:    Translation:HumansAnimals
    26. Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018 09; 82(3):407-418. PMID: 29926131.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    27. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. PMID: 29695765.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    28. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141. PMID: 29748008.
      Citations: 9     Fields:    Translation:Humans
    29. Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769. PMID: 29462132.
      Citations: 2     Fields:    Translation:Humans
    30. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2018; 8:9. PMID: 29456965.
      Citations:    
    31. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100. PMID: 29254498.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    32. Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. . 2018 03; 17(3):671-676. PMID: 29237802.
      Citations:    
    33. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963. PMID: 29162825.
      Citations: 6     Fields:    Translation:HumansCells
    34. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646. PMID: 29159766.
      Citations: 16     Fields:    Translation:Humans
    35. Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607. PMID: 29075985.
      Citations: 14     Fields:    Translation:Humans
    36. Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188. PMID: 29051321.
      Citations: 22     Fields:    Translation:HumansCells
    37. Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423. PMID: 29047029.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    38. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. PMID: 29082359.
      Citations:    
    39. Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson F, Gleber-Netto FO, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. Clin Cancer Res. 2017 Nov 01; 23(21):6541-6554. PMID: 28790110.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    40. Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173. PMID: 29152071.
      Citations:    Fields:    
    41. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Jul 20. PMID: 28729355.
      Citations: 1     Fields:    
    42. Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656. PMID: 28536309.
      Citations: 12     Fields:    Translation:Humans
    43. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806. PMID: 28430579.
      Citations: 2     Fields:    Translation:Humans
    44. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8). PMID: 28422758.
      Citations: 3     Fields:    
    45. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35. PMID: 28428884.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    46. Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 10; 35(5):616-626. PMID: 28194539.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    47. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444. PMID: 27882721.
      Citations: 6     Fields:    Translation:Humans
    48. Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20. PMID: 27802448.
      Citations:    Fields:    Translation:Humans
    49. Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215. PMID: 27599876.
      Citations: 3     Fields:    Translation:Humans
    50. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448. PMID: 27748430.
      Citations: 7     Fields:    Translation:Humans
    51. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531. PMID: 27589687.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    52. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365. PMID: 27729313.
      Citations: 53     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    53. Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs. 2017 02; 35(1):59-67. PMID: 27687047.
      Citations:    Fields:    Translation:Humans
    54. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396. PMID: 27649551.
      Citations: 77     Fields:    Translation:HumansCellsCTClinical Trials
    55. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. . 2016 10; 15(10):2475-2485. PMID: 27466356.
      Citations:    
    56. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409. PMID: 27412379.
      Citations: 6     Fields:    Translation:Humans
    57. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43. PMID: 27147567.
      Citations: 5     Fields:    Translation:Humans
    58. Gupta N, Hanley MJ, Venkatakrishnan K, Perez R, Norris RE, Nemunaitis J, Yang H, Qian MG, Falchook G, Labotka R, Fu S. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. Br J Clin Pharmacol. 2016 09; 82(3):728-38. PMID: 27121262.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    59. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. . 2016 06; 15(6):1397-404. PMID: 27207774.
      Citations:    
    60. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong DS, Kurzrock R. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701. PMID: 27197177.
      Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
    61. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38. PMID: 26933802.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    62. Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102. PMID: 27085994.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    63. Fu S, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Apr; 77(4):881. PMID: 26994910.
      Citations: 1     Fields:    
    64. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7. PMID: 27014780.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    65. Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul S, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 Mar; 77(3):575-81. PMID: 26825327.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    66. Siqing F, Culotta KS, Falchook GS, Hong DS, Myers AL, Zhang YP, Naing A, Janku F, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb; 77(2):357-64. PMID: 26698868.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    67. Wang Z, Fu S. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs. 2016; 25(1):15-30. PMID: 26560712.
      Citations: 3     Fields:    Translation:Humans
    68. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94. PMID: 26330075.
      Citations: 8     Fields:    Translation:Humans
    69. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. PMID: 26164085.
      Citations: 3     Fields:    Translation:Humans
    70. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. PMID: 26405159.
      Citations:    Fields:    
    71. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110. PMID: 26015395.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    72. Hong DS, Rosen P, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30; 6(21):18693-706. PMID: 26155941.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    73. Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):597-603. PMID: 26210681.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    74. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10. PMID: 26169970.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    75. Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2015 Jul; 53(7):563-72. PMID: 26073352.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    76. Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41. PMID: 26054632.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    77. Chen HH, Chen WC, Liang ZD, Tsai WB, Long Y, Aiba I, Fu S, Broaddus R, Liu J, Feun LG, Savaraj N, Kuo MT. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opin Ther Targets. 2015; 19(10):1307-17. PMID: 26004625.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    78. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20. PMID: 25990659.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    79. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. PMID: 25980577.
      Citations: 37     Fields:    Translation:Humans
    80. Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9. PMID: 25902899.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    81. Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31. PMID: 25822109.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    82. Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, Issa JP. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clin Epigenetics. 2015; 7:29. PMID: 25806091.
      Citations: 7     Fields:    
    83. Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54. PMID: 25680763.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    84. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018. PMID: 25669829.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    85. Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74. PMID: 25666183.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    86. Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79. PMID: 25426553.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    87. Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24. PMID: 25363205.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    88. Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86. PMID: 25323060.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    89. Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45. PMID: 25326232.
      Citations: 30     Fields:    Translation:Humans
    90. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46. PMID: 25313136.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    91. Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63. PMID: 25316815.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    92. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. . 2014 Dec; 13(12):3175-84. PMID: 25253784.
      Citations:    
    93. Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9. PMID: 25594061.
      Citations:    
    94. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26. PMID: 25087088.
      Citations: 6     Fields:    Translation:Humans
    95. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36. PMID: 24987059.
      Citations: 71     Fields:    Translation:Humans
    96. de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, Hong DS. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 2014 Dec; 14(6):468-74. PMID: 25065564.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    97. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9. PMID: 25003695.
      Citations: 6     Fields:    Translation:Humans
    98. Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12. PMID: 24919855.
      Citations: 18     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    99. Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38. PMID: 24912489.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    100. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54. PMID: 24811890.
      Citations: 31     Fields:    Translation:Humans
    101. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55. PMID: 24778042.
      Citations: 4     Fields:    Translation:Humans
    102. Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22. PMID: 24764123.
      Citations: 1     Fields:    Translation:Humans
    103. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66. PMID: 24746841.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    104. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73. PMID: 24752867.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    105. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55. PMID: 24742900.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    106. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45. PMID: 24742823.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    107. Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8. PMID: 24668327.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    108. Yang Y, Zhao LH, Fu SY, Lau WY, Lai EC, Gu FM, Wang ZG, Zhou WP. Selective hepatic vascular exclusion versus pringle maneuver in partial hepatectomy for liver hemangioma compressing or involving the major hepatic veins. Am Surg. 2014 Mar; 80(3):236-40. PMID: 24666863.
      Citations: 3     Fields:    Translation:Humans
    109. Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203. PMID: 24586081.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    110. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501. PMID: 24435060.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    111. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87. PMID: 24440717.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    112. Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82. PMID: 24356639.
      Citations: 2     Fields:    Translation:Humans
    113. Tang C, Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13. PMID: 25593979.
      Citations:    
    114. Naing A, Agarwal R, Falchook G, Hong DS, Janku F, Wheler J, Fu S, Kurzrock R. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 2013; 85(6):350-5. PMID: 24335388.
      Citations: 1     Fields:    Translation:Humans
    115. Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72. PMID: 24306314.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    116. Chen G, Liu J, Dong J, Li J, Fu S. GJB2 mutations are rare in probands with hearing loss in Chinese assortative mating families. Int J Pediatr Otorhinolaryngol. 2014 Feb; 78(2):244-7. PMID: 24359977.
      Citations:    Fields:    Translation:Humans
    117. Fu S, McQuinn L, Naing A, Wheler JJ, Janku F, Falchook GS, Piha-Paul SA, Tu D, Howard A, Tsimberidou A, Zinner R, Hong DS, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20. PMID: 24153239.
      Citations: 7     Fields:    Translation:Humans
    118. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. . 2013 Dec; 12(12):2857-63. PMID: 24092809.
      Citations:    
    119. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84. PMID: 24089446.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    120. Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology. 2013 Oct; 60(127):1611-23. PMID: 24634931.
      Citations: 4     Fields:    Translation:Humans
    121. Xu-Monette ZY, Møller MB, Tzankov A, Montes-Moreno S, Hu W, Manyam GC, Kristensen L, Fan L, Visco C, Dybkaer K, Chiu A, Tam W, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Wu L, Zhao X, Bueso-Ramos CE, Wang SA, Go RS, Li Y, Winter JN, Piris MA, Medeiros LJ, Young KH. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40. PMID: 23847722; PMCID: PMC3952598.
      Citations:    
    122. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. . 2013 Oct; 12(10):2167-75. PMID: 23963360.
      Citations:    
    123. Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200. PMID: 23907406.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    124. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, Fu S, Falchoock G, Tsimberidou AM, Piha-Paul S, Chisholm G, Kurzrock R. Body composition and survival in the early clinical trials setting. Eur J Cancer. 2013 Oct; 49(15):3068-75. PMID: 23867127.
      Citations: 9     Fields:    Translation:Humans
    125. Ganesan P, Piha-Paul S, Naing A, Falchook G, Wheler J, Fu S, Hong DS, Kurzrock R, Janku F, Laday S, Bedikian AY, Kies M, Wolff RA, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86. PMID: 23756764.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    126. Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget. 2013 Jun; 4(6):884-9. PMID: 23800680.
      Citations: 12     Fields:    Translation:HumansCells
    127. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. PMID: 23676418.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    128. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14. PMID: 23670029.
      Citations: 51     Fields:    Translation:Humans
    129. Wheler J, Falchook G, Tsimberidou AM, Hong D, Naing A, Piha-Paul S, Chen SS, Heymach J, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84. PMID: 23800712.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    130. Naing A, Fu S, Zinner RG, Wheler JJ, Hong DS, Arakawa K, Falchook GS, Kurzrock R. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs. 2014 Feb; 32(1):154-9. PMID: 23609829.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    131. Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65. PMID: 23576709.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    132. Li Y, Liu T, Ivan C, Huang J, Shen DY, Kavanagh JJ, Bast RC, Fu S, Hu W, Sood AK. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2013; 3:58. PMID: 23519775.
      Citations:    
    133. Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, Fu SY, Wu MC. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013 Mar; 257(3):490-505. PMID: 22868358.
      Citations: 37     Fields:    Translation:HumansCells
    134. Fu S, Barber D. Reply to M. Rouanne et al. J Clin Oncol. 2013 Feb 20; 31(6):818. PMID: 23544204.
      Citations:    Fields:    Translation:Humans
    135. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 05; 108(4):826-30. PMID: 23412108.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    136. Falchook GS, Naing A, Hong DS, Zinner R, Fu S, Piha-Paul SA, Tsimberidou AM, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013 Jan; 4(1):118-27. PMID: 23435217.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    137. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    138. Huang G, Yang Y, Shen F, Pan ZY, Fu SY, Lau WY, Zhou WP, Wu MC. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol. 2013 May; 20(5):1482-90. PMID: 23247982.
      Citations: 12     Fields:    Translation:HumansCells
    139. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75. PMID: 23248156.
      Citations: 38     Fields:    Translation:Humans
    140. Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97. PMID: 23143207.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    141. Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. Ann Oncol. 2013 Mar; 24(3):838-42. PMID: 23139256.
      Citations: 9     Fields:    Translation:Humans
    142. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84. PMID: 23066039.
      Citations: 109     Fields:    Translation:HumansCells
    143. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83. PMID: 22966018.
      Citations: 177     Fields:    Translation:Humans
    144. Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res. 2012 Sep 15; 72(18):4616-21. PMID: 22962276.
      Citations: 26     Fields:    Translation:Humans
    145. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805. PMID: 22927482.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    146. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic basis for overcoming platinum resistance using copper chelating agents. . 2012 Nov; 11(11):2483-94. PMID: 22914438.
      Citations:    
    147. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. . 2012 Sep; 13(11):1034-41. PMID: 22895067.
      Citations:    
    148. Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol. 2012 Aug 10; 30(23):2891-6. PMID: 22778314.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    149. Yang Y, Fu SY, Lau WY, Lai ECh, Li AJ, Pan ZY, Zhou WP, Shen F, Wu MC. Selective main portal vein clamping to minimize the risk of recurrence after curative liver resection for hepatocellular carcinoma. Hepatogastroenterology. 2012 Jul-Aug; 59(117):1560-5. PMID: 22683973.
      Citations: 7     Fields:    Translation:Humans
    150. Naing A, Veasey-Rodrigues H, Hong DS, Fu S, Falchook GS, Wheler JJ, Tsimberidou AM, Wen S, Fessahaye SN, Golden EC, Aaron J, Ewer MS, Kurzrock R. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol. 2012 Nov; 23(11):2960-2963. PMID: 22745218.
      Citations: 13     Fields:    Translation:Humans
    151. Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012 Dec 15; 118(24):6144-51. PMID: 22674635.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    152. Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology. 2012 Jun; 59(116):960-4. PMID: 22580643.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    153. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033. PMID: 22675430.
      Citations: 19     Fields:    Translation:HumansCells
    154. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303. PMID: 22537607.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    155. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. PMID: 22487539.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    156. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. . 2012 Jun; 11(6):1221-5. PMID: 22491798.
      Citations:    
    157. Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 01; 18(9):2625-31. PMID: 22465830.
      Citations: 81     Fields:    Translation:HumansCTClinical Trials
    158. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012 May 15; 18(10):2922-9. PMID: 22452943.
      Citations: 32     Fields:    Translation:Humans
    159. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol. 2012 Aug; 23(8):1963-1967. PMID: 22377564.
      Citations: 8     Fields:    Translation:Humans
    160. Hu WG, Lai EC, Liu H, Li AJ, Zhou WP, Fu SY, Pan ZY, Huang G, Lei Y, Lau WY, Wu MC. Diagnostic difficulties and treatment strategy of hepatic angiomyolipoma. Asian J Surg. 2011 Oct; 34(4):158-62. PMID: 22464831.
      Citations: 2     Fields:    Translation:Humans
    161. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82. PMID: 22271473.
      Citations: 184     Fields:    Translation:Humans
    162. Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer. 2012; 64(2):206-17. PMID: 22229660.
      Citations: 5     Fields:    Translation:Humans
    163. Chen P, Chen H, Fu S, Chen G, Dong J. Prevalence of GJB6 mutations in Chinese patients with non-syndromic hearing loss. Int J Pediatr Otorhinolaryngol. 2012 Feb; 76(2):265-7. PMID: 22186156.
      Citations: 3     Fields:    Translation:Humans
    164. Wang X, Fan J, Liu D, Fu S, Ingvarsson S, Chen H. Spreading of Alu methylation to the promoter of the MLH1 gene in gastrointestinal cancer. PLoS One. 2011; 6(10):e25913. PMID: 22022465.
      Citations: 7     Fields:    Translation:HumansCells
    165. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8. PMID: 21859821.
      Citations: 15     Fields:    Translation:Humans
    166. Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol. 2011 Sep 10; 29(26):3547-52. PMID: 21844494.
      Citations: 10     Fields:    Translation:Humans
    167. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 01; 118(5):1422-8. PMID: 21823111.
      Citations: 25     Fields:    Translation:Humans
    168. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769. PMID: 21829508.
      Citations: 81     Fields:    Translation:Humans
    169. Chen G, He F, Fu S, Dong J. GJB2 and mitochondrial DNA 1555A>G mutations in students with hearing loss in the Hubei Province of China. Int J Pediatr Otorhinolaryngol. 2011 Sep; 75(9):1156-9. PMID: 21777984.
      Citations: 2     Fields:    Translation:Humans
    170. Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. . 2011 Jul; 10(7):1300-7. PMID: 21571911.
      Citations:    
    171. Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R. Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer. 2011 Nov 15; 117(22):5142-50. PMID: 21538342.
      Citations: 19     Fields:    Translation:Humans
    172. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. . 2011 Mar; 10(3):558-65. PMID: 21216929.
      Citations:    
    173. Fu S, Yan J, Wang X, Dong J, Chen P, Wang C, Chen G. The audiological characteristics of a hereditary Y-linked hearing loss in a Chinese ethnic Tujia pedigree. Int J Pediatr Otorhinolaryngol. 2011 Feb; 75(2):202-6. PMID: 21130505.
      Citations: 1     Fields:    Translation:Humans
    174. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer. 2010 Dec; 9(5):311-4. PMID: 21208846.
      Citations: 1     Fields:    Translation:Humans
    175. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. PMID: 21472713.
      Citations: 62     Fields:    Translation:HumansCellsCTClinical Trials
    176. Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer. 2010 Oct 15; 116(20):4670-6. PMID: 20597137.
      Citations: 50     Fields:    Translation:HumansCells
    177. Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2011 Jul; 68(1):247-53. PMID: 20941597.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    178. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94. PMID: 20564148.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    179. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res. 2010 Aug 01; 16(15):4031-7. PMID: 20525754.
      Citations: 5     Fields:    Translation:Humans
    180. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1087-93. PMID: 20204368.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    181. Tang L, Lai EC, Cong WM, Li AJ, Fu SY, Pan ZY, Zhou WP, Lau WY, Wu MC. Inflammatory myofibroblastic tumor of the liver: a cohort study. World J Surg. 2010 Feb; 34(2):309-13. PMID: 20033408.
      Citations: 22     Fields:    Translation:Humans
    182. Cheng X, Moroney JW, Levenback CF, Fu S, Jaishuen A, Kavanagh JJ. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother. 2009 Nov; 21(5):566-72. PMID: 19933049.
      Citations: 6     Fields:    Translation:Humans
    183. Zheng H, Hu W, Deavers MT, Shen DY, Fu S, Li YF, Kavanagh JJ. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol. 2009 Oct; 201(4):367.e1-6. PMID: 19608149.
      Citations: 5     Fields:    Translation:HumansCells
    184. Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of phase 1 cancer clinical trials: new challenges in study requirements. Cancer. 2009 Apr 15; 115(8):1592-7. PMID: 19165808.
      Citations: 4     Fields:    
    185. Fu SY, Lai EC, Li AJ, Pan ZY, Yang Y, Sun YM, Lau WY, Wu MC, Zhou WP. Liver resection with selective hepatic vascular exclusion: a cohort study. Ann Surg. 2009 Apr; 249(4):624-7. PMID: 19300226.
      Citations: 8     Fields:    Translation:Humans
    186. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, Wu MC. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009 Feb; 249(2):195-202. PMID: 19212170.
      Citations: 59     Fields:    Translation:Humans
    187. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009 Feb; 200(2):177.e1-9. PMID: 19110234.
      Citations: 27     Fields:    Translation:HumansCells
    188. Tao X, Chon HS, Fu S, Kavanagh JJ, Hu W. Update on aurora kinase inhibitors in gynecologic malignancies. Recent Pat Anticancer Drug Discov. 2008 Nov; 3(3):162-77. PMID: 18991785.
      Citations: 2     Fields:    Translation:HumansAnimals
    189. Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ. Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res. 2008 Oct; 25(10):2272-82. PMID: 18509599.
      Citations: 1     Fields:    Translation:HumansCells
    190. Li AJ, Pan ZY, Zhou WP, Fu SY, Yang Y, Huang G, Yin L, Wu MC. Comparison of two methods of selective hepatic vascular exclusion for liver resection involving the roots of the hepatic veins. J Gastrointest Surg. 2008 Aug; 12(8):1383-90. PMID: 18509708.
      Citations: 3     Fields:    Translation:Humans
    191. Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):600-14. PMID: 17894799.
      Citations: 12     Fields:    Translation:Humans
    192. Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol. 2007 Aug; 106(2):375-80. PMID: 17512575.
      Citations: 3     Fields:    Translation:Humans
    193. Zhou WP, Li AJ, Fu SY, Pan ZY, Yang Y, Tang L, Wu MC. [Comparative study of selective hepatic vascular exclusion and Pringle maneuver in hepatectomy involving the second porta hepatis]. Zhonghua Wai Ke Za Zhi. 2007 May 01; 45(9):591-4. PMID: 17688790.
      Citations:    Fields:    Translation:Humans
    194. Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):325-38. PMID: 17362310.
      Citations: 16     Fields:    Translation:Humans
    195. Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug; 17(4):739-63. PMID: 17309673.
      Citations: 13     Fields:    Translation:Humans
    196. Fu S, Kavanagh JJ, Hu W, Bast RC. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1717-32. PMID: 17009963.
      Citations: 3     Fields:    Translation:Humans
    197. Wang X, Fu S, Freedman RS, Liu J, Kavanagh JJ. Immunobiology of gestational trophoblastic diseases. Int J Gynecol Cancer. 2006 Jul-Aug; 16(4):1500-15. PMID: 16884358.
      Citations: 1     Fields:    Translation:Humans
    198. Wang HY, Sun JM, Lu HF, Shi DR, Ou ZL, Ren YL, Fu SQ. Micrometastases detected by cytokeratin 19 expression in sentinel lymph nodes of patients with early-stage cervical cancer. Int J Gynecol Cancer. 2006 Mar-Apr; 16(2):643-8. PMID: 16681740.
      Citations: 11     Fields:    Translation:Humans
    199. Fu S, Hu W, Kavanagh JJ, Bast RC. Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets. 2006 Feb; 10(1):77-85. PMID: 16441230.
      Citations: 10     Fields:    Translation:HumansAnimals
    200. Wang X, Fu S, Freedman RS, Kavanagh JJ. Venous thromboembolism syndrome in gynecological cancer. Int J Gynecol Cancer. 2006 Jan-Feb; 16 Suppl 1:458-71. PMID: 16515646.
      Citations: 5     Fields:    Translation:Humans
    201. Fu S, Kavanagh JJ. First-line chemotherapy trial in advanced endometrial carcinoma. Curr Oncol Rep. 2004 Nov; 6(6):455. PMID: 15485614.
      Citations:    Fields:    
    202. Yin L, Fu S, Wang X, Nanakorn T, Won J, Deisseroth A. Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit. Chin Med J (Engl). 2001 Sep; 114(9):972-5. PMID: 11780394.
      Citations:    Fields:    Translation:HumansAnimalsCells
    203. Yin L, Zhao X, Fu S, Garacia-Sanchez F, Deisseroth AB. [Correlation of cell apoptosis induction with expression of human beta5 integrin on hematopoietic cells]. Zhonghua Xue Ye Xue Za Zhi. 2001 Jan; 22(1):13-6. PMID: 11877043.
      Citations:    Fields:    Translation:HumansCells
    204. Yin L, Fu S, Zhao X, Garcia-Sanchez F, Deisseroth AB. Correlation of cell proliferation inhibition and apoptosis induction with expression of human beta 5 integrin on hematopoietic cells. Chin Med J (Engl). 1999 Jul; 112(7):659-64. PMID: 11601265.
      Citations:    Fields:    Translation:HumansCells
    205. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A, et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res. 1998 Nov; 4(11):2717-21. PMID: 9829734.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    206. Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood. 1998 Jul 15; 92(2):672-82. PMID: 9657770.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    207. Deisseroth A, Guo D, Wang T, Fujii T, Fu SQ, Cote R, Savinov S, Liu F, Loewe R, Pizzorno G, Austin D, Crystal R, Chung I. Molecular therapy for cancer. Cancer J Sci Am. 1998 May; 4 Suppl 1:S5-7. PMID: 9619264.
      Citations:    Fields:    Translation:Humans
    208. Yin LH, Fu SQ, Nanakorn T, Garcia-Sanchez F, Chung I, Cote R, Pizzorno G, Hanania E, Heimfeld S, Crystal R, Deisseroth A. Results of retroviral and adenoviral approaches to cancer gene therapy. Stem Cells. 1998; 16 Suppl 1:247-50. PMID: 11012168.
      Citations: 5     Fields:    Translation:HumansCells
    209. Fu S, Deisseroth AB. Use of the cosmid adenoviral vector cloning system for the in vitro construction of recombinant adenoviral vectors. Hum Gene Ther. 1997 Jul 20; 8(11):1321-30. PMID: 9295127.
      Citations: 4     Fields:    Translation:Cells
    210. Fu SQ, Garcia Sanchez F, Chung I, Deisseroth A. Adenoviral vectors and hematopoietic cells. Blood. 1997 Feb 15; 89(4):1460-2. PMID: 9028971.
      Citations:    Fields:    Translation:HumansCells
    211. Hegewisch-Becker S, Hanania EG, Fu S, Körbling M, Deisseroth AB, Andreeff M. Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol. 1995 Aug; 90(4):876-83. PMID: 7669666.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    212. Hanania EG, Fu S, Roninson I, Zu Z, Deisseroth AB. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther. 1995 Jun; 2(4):279-84. PMID: 7552988.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    213. Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB. PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res. 1995 Jun; 1(6):583-90. PMID: 9816019.
      Citations: 6     Fields:    Translation:HumansCells
    214. Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Korbling M, Hester J, Durett A, Andreeff M, Mechetner E, Holzmayer T, et al. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther. 1995 Jun; 2(4):285-94. PMID: 7552989.
      Citations: 5     Fields:    Translation:HumansCells
    215. Hu G, Liu W, Hanania EG, Fu S, Wang T, Deisseroth AB. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther. 1995 Mar; 2(1):19-32. PMID: 7621252.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    216. Giles RE, Hanania EG, Fu S, Deisseroth A. Genetic therapy using bone marrow transplantation. Cancer Treat Res. 1995; 76:271-80. PMID: 7577339.
      Citations:    Fields:    Translation:HumansAnimalsCells
    217. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994 May 15; 83(10):3068-76. PMID: 7514051.
      Citations: 26     Fields:    Translation:HumansCells
    218. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang X, et al. Molecular approaches to the diagnosis and treatment of cancer. Stem Cells. 1993 Oct; 11 Suppl 3:129-30. PMID: 7905320.
      Citations:    Fields:    Translation:Humans
    219. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al. Genetic therapy of human neoplastic disease. J Hematother. 1993; 2(3):373-5. PMID: 7921999.
      Citations:    Fields:    Translation:HumansAnimalsCells
    220. Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821]. Oncotarget. 6:24581.
    221. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 6:26886-26894.
    222. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs. 33:621-631.
    223. The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatmentwith themammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab. Oncologist. 20:737-741.
    224. Targets by organ site.
    225. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discovery. 6:1352-1365.
    226. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 6:20099-20110.
    227. BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapeutics. 15:1397-1404.
    228. Targets by organ site.
    229. Enhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cells. Frontiers in Oncology. 3 MAR.
    230. Proteomics in gynecologic malignancies. American Journal of Cancer. 5:299-317.
    231. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma. Oncotarget. 6:28453-28462.
    232. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 1-6.
    233. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 6:12809-12821.
    234. Gene therapy. Cancer Bulletin. 45:139-145.
    235. Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer. Breast Cancer. 4:210-212.
    236. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clinical Cancer Research. 21:4801-4810.
    237. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 7:23227-23238.
    238. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology. 1-5.
    239. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 1:540-549.
    240. Targets by organ site.
    241. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials. Investigational New Drugs. 1-9.
    242. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 122:3401-3409.
    243. The Brave/Dagher/Farrell et al article reviewed. Oncology. 20:1410-1411.
    244. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 7:67521-67531.
    245. TP53 alterations correlate with response to VEGF/VEGFR inhibitors. Molecular Cancer Therapeutics. 15:2475-2485.
    246. International Journal of Cancer. 140:208-215.
    247. Survival of patients with metastatic leiomyosarcoma. Cancer Medicine. 5:3437-3444.
    248. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy (Proceedings of the National Academy of Sciences (December 24, 1996) 93 (15346-15351)). Proceedings of the National Academy of Sciences of the United States of America. 94:5495.
    249. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology (Switzerland).
    250. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports. 6.
    251. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    252. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investigational New Drugs.
    253. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer. Oncotarget. 7:35132-35143.
    254. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opinion on Therapeutic Targets. 19:1307-1317.
    255. Cancer therapy directed by comprehensive genomic profiling. Cancer Research. 76:3690-3701.
    256. Genetic therapy of human disease. Bone Marrow Transplantation. 15.
    257. Phase i study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7:1-11.
    258. MET nucleotide variations and amplification in advanced ovarian cancer. Oncoscience. 1:5-13.
    259. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 6:18693-18706.
    260. Erratum to. Cancer Chemotherapy and Pharmacology. 1.
    FU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (642)
    Explore
    _
    Co-Authors (150)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _